BACKGROUND: The progression from acute to chronic antibody-mediated rejection in kidney transplant recipients is usually not prevented by current therapeutic options. Here, we investigated whether the use of tofacitinib (TOFA), a Janus kinase 3 inhibitor, was capable of preventing the progression of allograft dysfunction in a Fisher-to-Lewis rat model of kidney transplantation. METHODS: Rats were treated from the third week after transplantation to allow the development of rejection. Treatment was based on cyclosporin A, rapamycin or TOFA. Renal function was assessed at 1, 4, 8, and 12 weeks after transplantation, whereas rat survival, histological lesions, and infiltrating lymphocytes were analyzed at 12 weeks. RESULTS: Tofacitinib prolonged graft survival, preserved tubular and glomerular structures and reduced humoral damage characterized by C4d deposition. Tofacitinib was able to reduce donor-specific antibodies. In addition, T and natural killer cell graft infiltration was reduced in TOFA-treated rats. Although rapamycin-treated rats also showed prolonged graft survival, glomerular structures were more affected. Moreover, only TOFA treatment reduced the presence of T, B and natural killer cells in splenic parenchyma. CONCLUSIONS: Tofacitinib is able to reduce the immune response generated in a rat model of kidney graft rejection, providing prolonged graft and recipient survival, better graft function, and less histological lesions.
BACKGROUND: The progression from acute to chronic antibody-mediated rejection in kidney transplant recipients is usually not prevented by current therapeutic options. Here, we investigated whether the use of tofacitinib (TOFA), a Janus kinase 3 inhibitor, was capable of preventing the progression of allograft dysfunction in a Fisher-to-Lewis rat model of kidney transplantation. METHODS:Rats were treated from the third week after transplantation to allow the development of rejection. Treatment was based on cyclosporin A, rapamycin or TOFA. Renal function was assessed at 1, 4, 8, and 12 weeks after transplantation, whereas rat survival, histological lesions, and infiltrating lymphocytes were analyzed at 12 weeks. RESULTS:Tofacitinib prolonged graft survival, preserved tubular and glomerular structures and reduced humoral damage characterized by C4d deposition. Tofacitinib was able to reduce donor-specific antibodies. In addition, T and natural killer cell graft infiltration was reduced in TOFA-treated rats. Although rapamycin-treated rats also showed prolonged graft survival, glomerular structures were more affected. Moreover, only TOFA treatment reduced the presence of T, B and natural killer cells in splenic parenchyma. CONCLUSIONS:Tofacitinib is able to reduce the immune response generated in a rat model of kidney graft rejection, providing prolonged graft and recipient survival, better graft function, and less histological lesions.
Authors: Sally Thomas; Katherine Fisher; John Snowden; Sarah Danson; Stephen Brown; Martin Zeidler Journal: Lancet Date: 2015-02-26 Impact factor: 79.321
Authors: Dominic C Borie; Michael J Larson; Mona G Flores; Andrew Campbell; Geraldine Rousvoal; Sally Zhang; John P Higgins; Douglas J Ball; Elizabeth M Kudlacz; William H Brissette; Eileen A Elliott; Bruce A Reitz; Paul S Changelian Journal: Transplantation Date: 2005-12-27 Impact factor: 4.939
Authors: Tobias Deuse; Xiaoqin Hua; Mandy Stubbendorff; Joshua M Spin; Evgenios Neofytou; Vanessa Taylor; Yan Chen; Gary Park; James B Fink; Thomas Renne; Martina Kiefmann; Rainer Kiefmann; Hermann Reichenspurner; Robert C Robbins; Sonja Schrepfer Journal: Transplantation Date: 2016-05 Impact factor: 4.939
Authors: Fritz Diekmann; Jordi Rovira; Joaquim Carreras; Edgar M Arellano; Elisenda Bañón-Maneus; María José Ramírez-Bajo; Alex Gutiérrez-Dalmau; Mercè Brunet; Josep M Campistol Journal: J Am Soc Nephrol Date: 2007-09-05 Impact factor: 10.121
Authors: E van Gurp; W Weimar; R Gaston; D Brennan; R Mendez; J Pirsch; S Swan; M D Pescovitz; G Ni; C Wang; S Krishnaswami; V Chow; G Chan Journal: Am J Transplant Date: 2008-06-28 Impact factor: 8.086
Authors: Young Ok Kim; Sun Woo Lim; Can Li; Hee Jung Kang; Kyung Ohk Ahn; Hyun Joo Yang; Jung Yeon Ghee; Su Hyun Kim; Jin Young Kim; Bum Soon Choi; Jin Kim; Chul Woo Yang Journal: Yonsei Med J Date: 2007-06-30 Impact factor: 2.759
Authors: María José Ramírez-Bajo; Javier Martín-Ramírez; Stefania Bruno; Chiara Pasquino; Elisenda Banon-Maneus; Jordi Rovira; Daniel Moya-Rull; Marta Lazo-Rodriguez; Josep M Campistol; Giovanni Camussi; Fritz Diekmann Journal: Front Cell Dev Biol Date: 2020-05-05
Authors: Fumi Varyani; Konstantinos Argyriou; Frank Phillips; Eirini Tsakiridou; Gordon William Moran Journal: Drug Des Devel Ther Date: 2019-12-02 Impact factor: 4.162
Authors: Maria Jose Ramirez-Bajo; Jordi Rovira; Marta Lazo-Rodriguez; Elisenda Banon-Maneus; Valeria Tubita; Daniel Moya-Rull; Natalia Hierro-Garcia; Pedro Ventura-Aguiar; Federico Oppenheimer; Josep M Campistol; Fritz Diekmann Journal: Front Cell Dev Biol Date: 2020-01-29